Page 40 - TD-1-2

Tumor Discovery Fact & challenges of immunotherapy in TNBC

Ethics approval and consent to participate 12. Bassez A, Vos H, Van Dyck L, et al., 2021, A single-cell
map of intratumoral changes during anti-PD1 treatment of
Not applicable. patients with breast cancer. Nat Med., 27(5): 820–832.
Consent for publication 13. Cheng AL, Qin S, Ikeda M, et al., 2022, Updated efficacy
and safety data from IMbrave150: Atezolizumab plus
Not applicable. bevacizumab vs. sorafenib for unresectable hepatocellular
carcinoma. J Hepatol., 76(4): 862-873.
Availability of data
14. Janjigian YY, Kawazoe A, Yanez P, et al., 2021, The
Not applicable. KEYNOTE-811 trial of dual PD-1 and HER2 blockade in
HER2-positive gastric cancer. Nature, 600(7890): 727–730.
References
15. Qin G, Wang X, Ye S, et al., 2020, NPM1 upregulates the
1. Valencia GA, Rioja P, Morante Z, et al., 2022, Immunotherapy transcription of PD-L1 and suppresses T cell activity in
in triple-negative breast cancer: A literature review and new triple-negative breast cancer. Nat Commun., 11(1): 1669.
advances. World J Clin Oncol., 13(3): 219–236.
16. Poveda A, Floquet A, Ledermann JA, et al., 2021, Olaparib
2. Gong Y, Ji P, Yang YS, et al., 2021, Metabolic-pathway-based tablets as maintenance therapy in patients with platinum-
subtyping of triple-negative breast cancer reveals potential sensitive relapsed ovarian cancer and a BRCA1/2 mutation
therapeutic targets. Cell Metab., 33(1): 51–64.e9. (SOLO2/ENGOT-Ov21): A final analysis of a double-blind,
3. Xiao Y, Ma D, Yang YS, et al., 2022, Comprehensive randomised, placebo-controlled, phase 3 trial. Lancet Oncol.,
metabolomics expands precision medicine for triple- 22(5): 620–631.
negative breast cancer. Cell Res., 32(5): 477–490. 17. Hu Z, Leet DE, Allesoe RL, et al., 2021, Personal neoantigen
4. Heeke AL, Tan AR, 2021, Checkpoint inhibitor therapy for vaccines induce persistent memory T cell responses and
metastatic triple-negative breast cancer. Cancer Metastasis epitope spreading in patients with melanoma. Nat Med.,
Rev., 40(2): 537–547. 27(3): 515–525.
5. Tarantino P, Gandini S, Trapani D, et al., 2021, 18. Spencer CN, McQuade JL, Gopalakrishnan V, et al., 2021,
Immunotherapy addition to neoadjuvant chemotherapy for Dietary fiber and probiotics influence the gut microbiome
early triple negative breast cancer: A systematic review and and melanoma immunotherapy response. Science,
meta-analysis of randomized clinical trials. Crit Rev Oncol 374(6575): 1632–1640.
Hematol., 159: 103223. 19. Nanda R, Chow LQ, Dees EC, et al., 2016, Pembrolizumab in
6. Colombo N, Dubot C, Lorusso D, et al., 2021, Pembrolizumab patients with advanced triple-negative breast cancer: Phase
for persistent, recurrent, or metastatic cervical cancer. Ib KEYNOTE-012 study. J Clin Oncol., 34(21): 2460–2467.
N Engl J Med., 385(20): 1856–1867. 20. Adams S, Schmid P, Rugo HS, et al., 2019, Pembrolizumab
7. Choueiri TK, Powles T, Burotto M, et al., 2021, Nivolumab monotherapy for previously treated metastatic triple-
plus cabozantinib versus sunitinib for advanced renal-cell negative breast cancer: Cohort A of the phase II
carcinoma. N Engl J Med., 384(9): 829–841. KEYNOTE-086 study. Ann Oncol., 30(3): 397–404.
8. Bellmunt J, Hussain M, Gschwend JE, et al., 2021, Adjuvant 21. Emens LA, Adams S, Barrios CH, et al., 2021, First-line
atezolizumab versus observation in muscle-invasive atezolizumab plus nab-paclitaxel for unresectable, locally
urothelial carcinoma (IMvigor010): A multicentre, open- advanced, or metastatic triple-negative breast cancer:
label, randomised, phase 3 trial. Lancet Oncol., 22(4): IMpassion130 final overall survival analysis. Ann Oncol.,
525–537. 32(8): 983–993.
9. Powles T, Sridhar SS, Loriot Y, et al., 2021, Avelumab 22. Thibault C, Elaidi R, Vano YA, et al., 2020, Open-label phase
maintenance in advanced urothelial carcinoma: Biomarker II to evaluate the efficacy of NEoadjuvant dose-dense MVAC
analysis of the phase 3 JAVELIN Bladder 100 trial. Nat Med., In combination with durvalumab and tremelimumab in
27(12): 2200–2211. muscle-invasive urothelial carcinoma: NEMIO. Bull Cancer,
107(5S): eS8–eS15.
10. Spigel DR, Faivre-Finn C, Gray JE, et al., 2022, Five-year
survival outcomes from the PACIFIC trial: Durvalumab 23. Gatti-Mays ME, Balko JM, Gameiro SR, et al., 2019, If we
after chemoradiotherapy in stage III non-small-cell lung build it they will come: Targeting the immune response to
cancer. J Clin Oncol., 40(12): 1301–1311. breast cancer. NPJ Breast Cancer, 5: 37.
11. Dirix LY, Takacs I, Jerusalem G, et al., 208, Avelumab, an 24. Yu S, Li X, Zhang J, et al., 2021, Development of a novel
anti-PD-L1 antibody, in patients with locally advanced or immune infiltration-based gene signature to predict
metastatic breast cancer: A phase 1b JAVELIN Solid Tumor prognosis and immunotherapy response of patients with
study. Breast Cancer Res Treat., 167(3): 671–686. cervical cancer. Front Immunol., 12: 709493.

Volume 1 Issue 2 (2022) 8 https://doi.org/10.36922/td.v1i2.196